Purging: Elimination of malignant cells from autologous blood or marrow transplants

Current Opinion in Oncology

Volumn 8, Issue 2, 1996, Pages 79-83

  Champlin, Richard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BUSULFAN; CD34 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; ETOPOSIDE; GAMMA INTERFERON; INTERLEUKIN 2; MAFOSFAMIDE; MONOCLONAL ANTIBODY; RIBOZYME; THY 1 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CELL DESTRUCTION; CHRONIC MYELOID LEUKEMIA; DRUG CYTOTOXICITY; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

EID: 0029990774     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199603000-00001     Document Type: Review

References (56)

1. Champlin R: Technology of blood and marrow transplantation. Exp Hematol 1995, 23:273.
2. Frei EI, Canellos GP: Dose: a critical factor in cancer chemotherapy. Am J Med 1980, 69:585.
3. Hryniuk WM, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984, 2:1281.
4. Champlin RE: Bone Marrow Transplantation. Boston: Kluwer Academic Publishers; 1990.
5. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993, 341:85.
6. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994, 84:380.
7. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994, 83:3068.
8. Sharp JG, Joshi SS, Armitage JO, Bierman P, Coccia PF, Harrington DS. Kessinger A, Crouse DA, Mann SL, Weisenburger DD: Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique. Blood 1992, 79:1074.
9. Gribbin JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991, 325:1525.
10. Lee MS, Chang KS, Cabanillas F, et al.: Detection of minimal residual cells carrying the t(14,18) by DNA sequence amplification. Science 1987, 237:175.
11. Negrin RS, Kiem H-P, Schmidt-Wolf IGH, Blume KG, Cleary ML: Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging. Blood 1991, 77:654.
12. Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK, Braine HG, Burke PJ, Ambinder RF, Burns WH, Fuller DJ, Davis JM, Sensenbrenner LL, Vogelsang GB, Wingard JR: Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986, 315:141.
13. Douay L, Mary J-Y, Giarratana M-C, Najman A, Gorin N-C: Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (ASTA Z 7557). Exp Hematol 1989, 17:429.
14. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, Carella A, Korbling M, Herve P, Maraninchi D, Löwenberg R, Verdonck LF, De Planque M, Hermans J, Helbig W, Porcellini A, Rizzoli V, Alesandrino EP, Franklin IM, Reiffers J, Colleselli P, Goldman JM: Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990, 75:1606.
15. Domenech J, Desbois I, Linassier C, Gihana E, Chenault S, Brémond J-L, Colombat P, Lamagnére J-P, Binet C: Sensitivity of human CFU-GM to mafosfamide: analysis of the factors affecting individual variations. Bone Marrow Transplant 1993, 11:425.
16. Hebert ME, Greenberg ML, Chaffee S, Gravatt L, Hershfield MS, Elion GB, Kurtzberg J: Pharmacologic purging of malignant T cells from human bone marrow using 9-b-D-arabinofuranosylguanine. Transplantation 1991, 52:634.
17. Gulati S, Acaba L, Yahalom J, Reich L, Motzer R, Crown J, Doherty M, Clarkson B, Berman E, Atzpodien J, Andreeff M, Gee T: Autologous bone marrow transplantation for acute myelogenous leukemia using 4-hydroperoxycyclophosphamide and VP-16 purged bone marrow. Bone Marrow Transplant 1992, 10:129.
18. Kühl J-S, Sikic BI, Blume KG, Chao NJ: Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model. Exp Hematol 1992, 20:1048.
19. Kapoor N, Tutschka PJ, Copelan EA: Bone marrow purging with glucocorticoids. Prog Clin Biol Res 1990, 333:39.
20. Miller CB, Zehnbauer BA, Piantadosi S, Rowley SD, Jones RJ: Correlation of occult clonogeneic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 1991, 78:1125.
21. Rowley SD, Zuehlsdorf M, Braine HG, Colvin OM, Davis J, Jones RJ, Saral R, Sensenbrenner LL, Yeager A, Santos G: CFU-GM content of bone marrow correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow. Blood 1987, 70:271.
22. Shah NK, Wingard JR, Piantadosi S, Rowley S, Santos G, Griffin CA: Chromosome abnormalities in patients treated with 4-hydroperoxycyclophosphamide-purged autologous bone marrow transplantation. Cancer Genet Cytogenet 1993, 65:135.
23. Kalechman Y, Sotnik-Barkai I, Albeck M, Sredni B: Protection of bone marrow stromal cells from the toxic effects of cyclophosphamide in vivo and of ASTA-Z 7557 and etoposide in vitro by ammonium trichloro(dioxyethylene-O-O′)tellurate (AS101). Cancer Res 1993, 53:1838.
24. Ritz J, Sallan SE, Bast RC, Lipton JM, Clavell LA, Feeney M, Hercend T, Nathan DG, Schlossman SF: Autologous bone marrow transplantation in CALLA positive acute lymphoblastic leukemia after in vitro treatment with J5 monoclonal antibody and complement. Lancet 1982, ii:60.
25. Roy DC, Perreault C, Bélanger R, Gyger M, Le Houillier C, Blättler WA, Lambert JM, Ritz J: Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin. J Clin Immunol 1995, 15:51.
26. + B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein. Blood 1992, 79:3369.
27. Dickinson AM, Middleton SL, Latham J, Dunn J, Thomas L, Proctor SJ: Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis. Leukemia 1995, 9:444.
28. Van den Brink MRM, Voogt PJ, Marijt WAF, Van Luxemburg-Heys SAP, van Rood JJ, Brand A: Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro. Blood 1989, 74:354.
29. Verma UN, Bagg A, Brown E, Mazumder A: Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors. Bone Marrow Transplant 1994, 13:115.
30. Klingemann H-G, Eaves CJ, Barnett MJ, Eaves AC, Hogge DE, Nantel SH, Reece E, Shepherd JD, Sutherland HJ, Phillips GL: Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 1994, 14:389.
31. Becker M, Fabrega S, Belloc F, Rice A, Barbu V, Reiffers J: Interferon gamma is effective for BM purging in a patient with CML. Bone Marrow Transplant 1993, 12:155.
32. Skorski T, Nieborowska-Skorska M, Barletta C, Malaguarnera L, Szczylik C, Chen S-T, Lange B, Calabretta B: Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J Clin Invest 1993, 92:194.
33. Snyder DS, Wu Y, Wang JL, Rossi JJ, Swiderski P, Kaplan BE, Forman SJ: Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 1993, 82:600.
34. Yuan T, Zhou YQ, Herst CV, Reading C, Ellersen D, Etkin M, Khouri I, Kantarjian H, Talpaz M, Deisseroth A: Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation. Prog Clin Biol Res 1992, 377:227.
35. Gewirtz AM: Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides. Bone Marrow Transplant 1994, 14(suppl 3):S57.
36. Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M, Gewirtz AM: Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci U S A 1991, 88:2351.
37. Trapnell BC, Gorziglia M: Gene therapy using adenoviral vectors. Curr Opin Biotechnol 1994, 5:617.
38. Lebkowski JS, Schain LR, Okrongly D, Levinsky R, Harvey MJ, Okarma TB: Rapid isolation of human CD34 hematopoietic stem cells: purging of human tumor cells. Transplantation 1992, 53:1011.
39. Civin CI: Identification and positive selection of human progenitor/stem cells for bone marrow transplantation. Prog Clin Biol Res 1992, 377:461.
40. Shpall EJ, Jones RB, Bearman SI, Franklin WA, Archer PG, Curiel T, Bitter M, Claman HN, Stemmer SM, Purdy M, Myers SE, Hami L, Taffs S, Heimfeld S, Hallagan J, Berenson RJ: Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994, 12:28.
41. + marrow cells in patients with breast cancer or neuroblastoma. Blood 1991, 77:1717.
42. Lane TA, Law P, Maruyama M, Young D, Burgess J, Mullen M, Mealiffe M, Terstappen LWMM, Hardwick A, Moubayed M, Oldham F, Corringham RET, Ho AD: Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995, 85:275.
43. Baum CM, Weissman IL, Tsukamoto AS, Buckle A-M, Peault B: Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A 1992, 89:2804.
44. Negrin RS, Kusnierz-Glaz CR, Still BJ, Schriber JR, Chao NJ, Long GD, Hoyle C, Hu WW, Horning SJ, Brown BW, Blume KG, Stober S: Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 1994, 84:396a.
45. Rohatiner AZS, Johnson PWM, Price CGA, Arnott SJ, Amess JAL, Norton AJ, Dorey E, Adams K, Whelan JS, Matthews J, MacCallum PK, Oza AM, Lister TA: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994, 12:1177.
46. Sallan SE, Niemeyer CM, Billett AL, Lipton JM, Tarbell NJ, Gelber RD, Murray C, Pittinger TP, Wolfe LC, Bast RC Jr, Ritz J: Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol 1989, 7:1594.
47. Soiffer RJ, Roy DC, Gonin R, Murray C, Anderson KC, Freedman AS, Rabinowe SN, Robertson MJ, Spector N, Pesek K, Mauch P, Nadler LM, Ritz J: Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant 1993, 12:243.
48. Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, Pileri A: High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995, 85:1596.
49. + peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995, 85:436.
50. Anderson KC, Andersen J, Soiffer R, Freedman AS, Rabinowe SN, Robertson MJ, Spector N, Blake K, Murray C, Freeman A, Coral F, Marcus KC, Mauch P, Nadler LM, Ritz J: Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood 1993, 82:2568.
51. Vescio RA, Hong CH, Cao J, Kim A, Schiller GJ, Lichtenstein AK, Berenson RJ, Berenson JR: The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 1994, 84:3283.
52. Kapelushnik J, Nagler A, Or R, Naparstek E, Cividalli G, Aker M, Mehta J, Mumcuoglu M, Slavin S: Autologous bone marrow transplantation for stage IV neuroblastoma: the role of soybean agglutinin purging. Transplant Proc 1993, 25:2375.
53. Moriyama Y, Goto T, Hashimoto S, Furukawa T, Kishi K, Takahashi M, Shibata A: A simple elimination of clonogenic tumor cells from human bone marrow in vitro by heat: its application to autologous bone marrow transplantation for B-cell lymphoma. Ann Hematol 1992, 64:266.
54. Murphy PB, Richman CM: Normal and malignant human myeloid progenitors differ in their sensitivity to hyperthermia. Exp Hematol 1989, 17:1105.
55. Gidáli J, Fehér I: The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells. Bone Marrow Transplant 1992, 10:479.
56. Itoh T, Messner HA, Jamal N, Tweeddale M, Sieber F: Merocyanine 540-sensitized photoinactivation of high-grade non-Hodgkin's lymphoma cells: potential application in autologous BMT. Bone Marrow Transplant 1993, 12:191.